微小残存疾患市場は、2024年の14億3000万ドルから2029年には25億5000万ドルに成長し、予測期間中のCAGRは12.2%になると予想されます。この市場に関与する主要な市場プレーヤーは、F. Hoffmann-La Roche Ltd. (スイス)、Labcorp Inc. (米国)、Guardant Health (米国)、シスメックス株式会社 (日本)、NeoGenomics Laboratories, Inc. (米国)、Adaptive Biotechnologies Corporation (米国)、ArcherDX, Inc. (米国)、Asuragen Inc. (米国)、Arup Laboratories Inc. (米国)、Bio-Rad Laboratories, Inc. (米国)、Cergentis B.V. (オランダ)、Molecular MD(ICON plc) (アイルランド)、Invivoscribe, Inc. (米国)、 Mission Bio, Inc. (米国)、Natera, Inc. (米国)、Opko Health, Inc. (米国)、Quest Diagnostics (米国)、Genetron Health (中国)など。
目次
TABLE OF CONTENTS
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED & REGIONAL SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Primary sources
2.2.2.2 Key data from primary sources
2.2.2.3 Key industry insights
2.2.2.4 Breakdown of primary interviews
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation
2.3.1.2 Approach 2: Presentations of companies and primary interviews
2.3.1.3 Growth forecast
2.3.1.4 CAGR projections
2.3.2 TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN & DATA TRIANGULATION
2.5 MARKET SHARE ESTIMATION
2.6 STUDY ASSUMPTIONS
2.7 GROWTH RATE ASSUMPTIONS
2.8 RESEARCH LIMITATIONS
2.9 RISK ASSESSMENT
2.9.1 RISK ASSESSMENT: MINIMAL RESIDUAL DISEASE TESTING MARKET
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 MINIMAL RESIDUAL DISEASE TESTING MARKET OVERVIEW
4.2 MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY PRODUCT, 2024 VS. 2029
4.3 MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY TECHNOLOGY, 2024 VS. 2029
4.4 MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY APPLICATION, 2024 VS. 2029
4.5 MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY END USER, 2024 VS. 2029
4.6 MINIMAL RESIDUAL DISEASE TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Rising incidence of hematological malignancies
5.2.1.2 Increasing collaborations and partnerships between pharmaceutical companies and product manufacturers
5.2.1.3 Increasing cancer awareness initiatives by global health organizations
5.2.2 RESTRAINTS
5.2.2.1 Complex regulatory frameworks delaying approvals of new molecular diagnostics tests
5.2.2.2 High cost of minimal residual disease testing kits
5.2.3 OPPORTUNITIES
5.2.3.1 Growth opportunities in emerging countries
5.2.4 CHALLENGES
5.2.4.1 Unclear reimbursement scenario and policies for patients
5.3 PRICING ANALYSIS
5.3.1 INDICATIVE PRICING TREND OF KEY PLAYERS, BY PRODUCT & REGION
5.4 PATENT ANALYSIS
5.4.1 LIST OF MAJOR PATENTS
5.5 VALUE CHAIN ANALYSIS
5.6 SUPPLY CHAIN ANALYSIS
5.7 TRADE ANALYSIS
5.7.1 IMPORT DATA
5.7.2 EXPORT DATA
5.8 ECOSYSTEM ANALYSIS
5.8.1 ROLE IN ECOSYSTEM
5.9 PORTER'S FIVE FORCES ANALYSIS
5.9.1 THREAT OF NEW ENTRANTS
5.9.2 THREAT OF SUBSTITUTES
5.9.3 BARGAINING POWER OF BUYERS
5.9.4 BARGAINING POWER OF SUPPLIERS
5.9.5 INTENSITY OF COMPETITIVE RIVALRY
5.10 KEY STAKEHOLDERS & BUYING CRITERIA
5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.10.2 BUYING CRITERIA
5.11 REGULATORY ANALYSIS
5.11.1 REGULATORY LANDSCAPE
5.11.1.1 North America
5.11.1.1.1 US
5.11.1.1.2 Canada
5.11.1.2 Europe
5.11.1.3 Asia Pacific
5.11.1.3.1 China
5.11.1.3.2 Japan
5.11.1.4 Latin America
5.11.1.4.1 Brazil
5.11.1.4.2 Mexico
5.11.1.5 Middle East
5.11.1.6 Africa
5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.12 TECHNOLOGY ANALYSIS
5.12.1 KEY TECHNOLOGIES
5.12.1.1 PCR and NGS
5.12.2 ADJACENT TECHNOLOGIES
5.12.2.1 Digital PCR
5.13 KEY CONFERENCES & EVENTS IN 2023-2024
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
5.15 INVESTMENT & FUNDING SCENARIO
5.16 CASE STUDY ANALYSIS
5.17 IMPACT OF AI/GEN AI ON MINIMAL RESIDUAL DISEASE TESTING MARKET
6 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 ASSAY KITS & REAGENTS
6.2.1 INCREASING AWARENESS ABOUT EARLY DISEASE DETECTION AND PREVENTIVE HEALTHCARE TO PROPEL MARKET
6.3 INSTRUMENTS
6.3.1 RISING NEED FOR FASTER AND MORE ACCURATE TEST RESULTS TO DRIVE MARKET GROWTH
7 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
7.2 POLYMERASE CHAIN REACTION
7.2.1 COST BENEFITS OF PCR TECHNOLOGY TO DRIVE ADOPTION
7.3 NEXT-GENERATION SEQUENCING
7.3.1 HIGH SENSITIVITY AND ECONOMIC BENEFITS TO SUPPORT ADOPTION
7.4 FLOW CYTOMETRY
7.4.1 GROWING INCIDENCE AND PREVALENCE OF CANCER TO PROPEL MARKET GROWTH
7.5 OTHER TECHNOLOGIES
8 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION
8.1 INTRODUCTION
8.2 HEMATOLOGICAL MALIGNANCIES
8.2.1 LEUKEMIA
8.2.1.1 Myeloid leukemia
8.2.1.1.1 High prevalence of AML in adults to support growth
8.2.1.2 Lymphocytic leukemia
8.2.1.2.1 High incidence of ALL in children to drive market
8.2.1.3 Other leukemias
8.2.2 LYMPHOMA
8.2.2.1 Non-Hodgkin lymphoma
8.2.2.1.1 Growing consumption of medications that suppress immune system to drive growth
8.2.2.2 Hodgkin lymphoma
8.2.2.2.1 Growing incidence of Hodgkin lymphoma to propel demand for MRD testing
8.3 SOLID TUMORS
8.3.1 ABILITY OF MRD TO ASSESS TREATMENT RESPONSE TO FUEL GROWTH
8.4 MULTIPLE MYELOMA
8.4.1 RISING INCIDENCE OF MULTIPLE MYELOMAS TO DRIVE MARKET
8.5 OTHER APPLICATIONS
9 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER
9.1 INTRODUCTION
9.2 HOSPITALS & SPECIALTY CLINICS
9.2.1 INCREASING NUMBER OF PATIENTS VISITING HOSPITALS TO DRIVE GROWTH
9.3 DIAGNOSTIC LABORATORIES
9.3.1 ROBUST INFRASTRUCTURE AND SPECIALIZED TESTING CAPABILITIES TO SUPPORT GROWTH
9.4 ACADEMIC & RESEARCH INSTITUTES
9.4.1 INCREASING RESEARCH ACTIVITIES TO BOOST MARKET
9.5 OTHER END USERS
10 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
10.2.2 US
10.2.2.1 Increasing prevalence of cancer to drive market
10.2.3 CANADA
10.2.3.1 Availability of various cancer screening programs to support market growth
10.3 EUROPE
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
10.3.2 GERMANY
10.3.2.1 Government support for research funding to support MRD testing market
10.3.3 UK
10.3.3.1 Increasing number of diagnostic laboratories to propel market growth
10.3.4 FRANCE
10.3.4.1 Rising R&D expenditure in France to drive market
10.3.5 ITALY
10.3.5.1 Favorable funding scenario to drive market
10.3.6 SPAIN
10.3.6.1 Consolidation of laboratories in Spain to support market growth
10.3.7 REST OF EUROPE
10.4 ASIA PACIFIC
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
10.4.2 CHINA
10.4.2.1 Growing public access to advanced healthcare facilities to drive market
10.4.3 JAPAN
10.4.3.1 Universal healthcare reimbursement policy to support market growth
10.4.4 INDIA
10.4.4.1 Increasing private and public investments in healthcare system to drive market
10.4.5 REST OF ASIA PACIFIC
10.5 LATIN AMERICA
10.5.1 INCREASING PRIVATE AND PUBLIC INVESTMENTS TO DRIVE MARKET
10.5.2 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
10.6 MIDDLE EAST & AFRICA
10.6.1 INCREASING FUNDING IN RESEARCH TO DRIVE MARKET
10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
10.7 GCC COUNTRIES
10.7.1 RISING FOCUS ON ADVANCED HEALTH INFRASTRUCTURE AND FUNDING IN RESEARCH TO DRIVE GCC MARKET
10.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
11.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN MINIMAL RESIDUAL DISEASE TESTING MARKET
11.3 REVENUE ANALYSIS, 2019-2023
11.4 MARKET SHARE ANALYSIS, 2023
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
11.5.1 LIST OF EVALUATED VENDORS
11.5.2 STARS
11.5.3 EMERGING LEADERS
11.5.4 PERVASIVE PLAYERS
11.5.5 PARTICIPANTS
11.5.6 COMPANY FOOTPRINT: KEY PLAYERS, 2023
11.5.6.1 Company footprint
11.5.6.2 Product footprint
11.5.6.3 Technology footprint
11.5.6.4 Application footprint
11.5.6.5 Region footprint
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
11.6.1 PROGRESSIVE COMPANIES
11.6.2 RESPONSIVE COMPANIES
11.6.3 DYNAMIC COMPANIES
11.6.4 STARTING BLOCKS
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
11.7 COMPANY VALUATION & FINANCIAL METRICS
11.8 BRAND/PRODUCT COMPARISON
11.9 COMPETITIVE SCENARIO
11.9.1 PRODUCT LAUNCHES
11.9.2 DEALS
12 COMPANY PROFILES
12.1 KEY PLAYERS
12.1.1 F. HOFFMANN-LA ROCHE AG
12.1.1.1 Business overview
12.1.1.2 Products offered
12.1.1.3 Recent developments
12.1.1.3.1 Product launches
12.1.1.4 MnM view
12.1.1.4.1 Right to win
12.1.1.4.2 Strategic choices
12.1.1.4.3 Weaknesses & competitive threats
12.1.2 LABORATORY CORPORATION OF AMERICA HOLDINGS
12.1.2.1 Business overview
12.1.2.2 Products offered
12.1.2.3 Recent developments
12.1.2.3.1 Deals
12.1.2.4 MnM view
12.1.2.4.1 Right to win
12.1.2.4.2 Strategic choices
12.1.2.4.3 Weaknesses & competitive threats
12.1.3 GUARDANT HEALTH, INC.
12.1.3.1 Business overview
12.1.3.2 Products offered
12.1.3.3 Recent developments
12.1.3.3.1 Product launches & approvals
12.1.3.3.2 Deals
12.1.3.4 MnM view
12.1.3.4.1 Right to win
12.1.3.4.2 Strategic choices
12.1.3.4.3 Weaknesses & competitive threats
12.1.4 SYSMEX CORPORATION
12.1.4.1 Business overview
12.1.4.2 Products offered
12.1.4.3 Recent developments
12.1.4.3.1 Product launches
12.1.4.4 MnM view
12.1.4.4.1 Right to win
12.1.4.4.2 Strategic choices
12.1.4.4.3 Weaknesses & competitive threats
12.1.5 NEOGENOMICS LABORATORIES
12.1.5.1 Business overview
12.1.5.2 Products offered
12.1.5.3 Recent developments
12.1.5.3.1 Deals
12.1.5.4 MnM view
12.1.5.4.1 Right to win
12.1.5.4.2 Strategic choices
12.1.5.4.3 Weaknesses & competitive threats
12.1.6 MOLECULARMD (A SUBSIDIARY OF ICON PLC)
12.1.6.1 Business overview
12.1.6.2 Products offered
12.1.7 ADAPTIVE BIOTECHNOLOGIES
12.1.7.1 Business overview
12.1.7.2 Products offered
12.1.7.3 Recent developments
12.1.7.3.1 Deals
12.1.8 ARCHERDX (INVITAE CORPORATION)
12.1.8.1 Business overview
12.1.8.2 Products offered
12.1.8.3 Recent developments
12.1.8.3.1 Product launches
12.1.8.3.2 Deals
12.1.9 BIO-RAD LABORATORIES, INC.
12.1.9.1 Business overview
12.1.9.2 Products offered
12.1.10 NATERA, INC.
12.1.10.1 Business overview
12.1.10.2 Products offered
12.2 OTHER PLAYERS
12.2.1 OPKO HEALTH, INC.
12.2.2 GENETRON HEALTH
12.2.3 QUEST DIAGNOSTICS, INC.
12.2.4 ASURAGEN, INC.
12.2.5 INVIVOSCRIBE, INC.
12.2.6 ARUP LABORATORIES INC.
12.2.7 MISSION BIO, INC.
12.2.8 CERGENTIS B.V.
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
List of Tables
TABLE 1 HEMATOLOGIC CANCER INCIDENCE, BY TYPE, 2023
TABLE 2 INCIDENCE OF HEMATOLOGIC CANCERS, BY COUNTRY, 2023 VS. 2030
TABLE 3 INDICATIVE PRICE OF MRD TESTING PRODUCTS, BY PRODUCT & REGION, 2022-2024
TABLE 4 LIST OF KEY PATENTS IN MINIMAL RESIDUAL DISEASE TESTING MARKET
TABLE 5 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2019-2023 (USD MILLION)
TABLE 6 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2019-2023 (USD MILLION)
TABLE 7 MINIMAL RESIDUAL DISEASE TESTING MARKET: ROLE IN ECOSYSTEM
TABLE 8 MINIMAL RESIDUAL DISEASE TESTING MARKET: PORTER'S FIVE FORCES ANALYSIS
TABLE 9 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF MRD TESTS (%)
TABLE 10 KEY BUYING CRITERIA FOR MRD TESTS, BY END USER
TABLE 11 CHINA: CLASSIFICATION OF MEDICAL DEVICES
TABLE 12 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA
TABLE 13 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 15 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 16 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 17 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 18 MINIMAL RESIDUAL DISEASE TESTING MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
TABLE 19 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 20 KEY ASSAY KITS & REAGENTS AVAILABLE IN MARKET
TABLE 21 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR ASSAY KITS & REAGENTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 22 KEY INSTRUMENTS AVAILABLE IN MARKET
TABLE 23 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR INSTRUMENTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 24 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 25 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR PCR, BY REGION, 2022-2029 (USD MILLION)
TABLE 26 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR NGS, BY REGION, 2022-2029 (USD MILLION)
TABLE 27 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR FLOW CYTOMETRY, BY REGION, 2022-2029 (USD MILLION)
TABLE 28 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2022-2029 (USD MILLION)
TABLE 29 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 30 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 31 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY REGION, 2022-2029 (USD MILLION)
TABLE 32 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 33 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 34 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 35 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022-2029 (USD MILLION)
TABLE 36 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY REGION, 2022-2029 (USD MILLION)
TABLE 37 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 38 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 39 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 40 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR MYELOID LEUKEMIA, BY REGION, 2022-2029 (USD MILLION)
TABLE 41 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR MYELOID LEUKEMIA, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 42 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR MYELOID LEUKEMIA, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 43 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR MYELOID LEUKEMIA, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 44 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOCYTIC LEUKEMIA, BY REGION, 2022-2029 (USD MILLION)
TABLE 45 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOCYTIC LEUKEMIA, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 46 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOCYTIC LEUKEMIA, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 47 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOCYTIC LEUKEMIA, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 48 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER LEUKEMIAS, BY REGION, 2022-2029 (USD MILLION)
TABLE 49 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER LEUKEMIAS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 50 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER LEUKEMIAS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 51 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER LEUKEMIAS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 52 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022-2029 (USD MILLION)
TABLE 53 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY REGION, 2022-2029 (USD MILLION)
TABLE 54 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 55 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 56 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 57 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR NON-HODGKIN LYMPHOMA, BY REGION, 2022-2029 (USD MILLION)
TABLE 58 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR NON-HODGKIN LYMPHOMA, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 59 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR NON-HODGKIN LYMPHOMA, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 60 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR NON-HODGKIN LYMPHOMA, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 61 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HODGKIN LYMPHOMA, BY REGION, 2022-2029 (USD MILLION)
TABLE 62 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HODGKIN LYMPHOMA, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 63 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HODGKIN LYMPHOMA, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 64 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HODGKIN LYMPHOMA, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 65 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR SOLID TUMORS, BY REGION, 2022-2029 (USD MILLION)
TABLE 66 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR SOLID TUMORS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 67 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR SOLID TUMORS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 68 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR SOLID TUMORS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 69 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR MULTIPLE MYELOMA, BY REGION, 2022-2029 (USD MILLION)
TABLE 70 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR MULTIPLE MYELOMA, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 71 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR MULTIPLE MYELOMA, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 72 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR MULTIPLE MYELOMA, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 73 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
TABLE 74 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 75 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 76 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 77 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 78 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2022-2029 (USD MILLION)
TABLE 79 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2022-2029 (USD MILLION)
TABLE 80 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2022-2029 (USD MILLION)
TABLE 81 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER END USERS, BY REGION, 2022-2029 (USD MILLION)
TABLE 82 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 83 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 84 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 85 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 86 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 87 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 88 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022-2029 (USD MILLION)
TABLE 89 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022-2029 (USD MILLION)
TABLE 90 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 91 US: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 92 US: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 93 US: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 94 US: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 95 US: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022-2029 (USD MILLION)
TABLE 96 US: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022-2029 (USD MILLION)
TABLE 97 US: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 98 CANADA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 99 CANADA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 100 CANADA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 101 CANADA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 102 CANADA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022-2029 (USD MILLION)
TABLE 103 CANADA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022-2029 (USD MILLION)
TABLE 104 CANADA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 105 EUROPE: FORECAST OF LEUKEMIA CASES, BY COUNTRY, 2025 VS. 2030 VS. 2035
TABLE 106 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 107 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 108 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 109 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 110 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 111 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022-2029 (USD MILLION)
TABLE 112 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022-2029 (USD MILLION)
TABLE 113 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 114 GERMANY: CANCER INCIDENCE, BY TYPE, 2022
TABLE 115 GERMANY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 116 GERMANY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 117 GERMANY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 118 GERMANY: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 119 GERMANY: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022-2029 (USD MILLION)
TABLE 120 GERMANY: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022-2029 (USD MILLION)
TABLE 121 GERMANY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 122 UK: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 123 UK: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 124 UK: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 125 UK: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 126 UK: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022-2029 (USD MILLION)
TABLE 127 UK: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022-2029 (USD MILLION)
TABLE 128 UK: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 129 FRANCE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 130 FRANCE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 131 FRANCE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 132 FRANCE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 133 FRANCE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022-2029 (USD MILLION)
TABLE 134 FRANCE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022-2029 (USD MILLION)
TABLE 135 FRANCE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 136 ITALY: HEMATOLOGICAL CANCER INCIDENCE, BY TYPE, 2022
TABLE 137 ITALY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 138 ITALY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 139 ITALY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 140 ITALY: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 141 ITALY: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022-2029 (USD MILLION)
TABLE 142 ITALY: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022-2029 (USD MILLION)
TABLE 143 ITALY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 144 SPAIN: HEMATOLOGICAL CANCER INCIDENCE, BY TYPE, 2022
TABLE 145 SPAIN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 146 SPAIN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 147 SPAIN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 148 SPAIN: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 149 SPAIN: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022-2029 (USD MILLION)
TABLE 150 SPAIN: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022-2029 (USD MILLION)
TABLE 151 SPAIN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 152 REST OF EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 153 REST OF EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 154 REST OF EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 155 REST OF EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 156 REST OF EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022-2029 (USD MILLION)
TABLE 157 REST OF EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022-2029 (USD MILLION)
TABLE 158 REST OF EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 159 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 160 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 161 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 162 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 163 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 164 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022-2029 (USD MILLION)
TABLE 165 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022-2029 (USD MILLION)
TABLE 166 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 167 CHINA: HEMATOLOGICAL CANCER INCIDENCE, BY TYPE, 2022
TABLE 168 CHINA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 169 CHINA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 170 CHINA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 171 CHINA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 172 CHINA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022-2029 (USD MILLION)
TABLE 173 CHINA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022-2029 (USD MILLION)
TABLE 174 CHINA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 175 JAPAN: HEMATOLOGY CANCER INCIDENCE, BY TYPE, 2022
TABLE 176 JAPAN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 177 JAPAN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 178 JAPAN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 179 JAPAN: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 180 JAPAN: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022-2029 (USD MILLION)
TABLE 181 JAPAN: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022-2029 (USD MILLION)
TABLE 182 JAPAN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 183 INDIA: HEMATOLOGY CANCER INCIDENCE, BY TYPE, 2022
TABLE 184 INDIA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 185 INDIA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 186 INDIA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 187 INDIA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 188 INDIA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022-2029 (USD MILLION)
TABLE 189 INDIA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022-2029 (USD MILLION)
TABLE 190 INDIA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 191 REST OF ASIA PACIFIC: GERIATRIC POPULATION, BY COUNTRY, 2023
TABLE 192 REST OF ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 193 REST OF ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 194 REST OF ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 195 REST OF ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 196 REST OF ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022-2029 (USD MILLION)
TABLE 197 REST OF ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022-2029 (USD MILLION)
TABLE 198 REST OF ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 199 LATIN AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 200 LATIN AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 201 LATIN AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 202 LATIN AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 203 LATIN AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022-2029 (USD MILLION)
TABLE 204 LATIN AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022-2029 (USD MILLION)
TABLE 205 LATIN AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 206 MIDDLE EAST & AFRICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 207 MIDDLE EAST & AFRICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 208 MIDDLE EAST & AFRICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 209 MIDDLE EAST & AFRICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 210 MIDDLE EAST & AFRICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022-2029 (USD MILLION)
TABLE 211 MIDDLE EAST & AFRICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022-2029 (USD MILLION)
TABLE 212 MIDDLE EAST & AFRICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 213 GCC COUNTRIES: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 214 GCC COUNTRIES: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 215 GCC COUNTRIES: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 216 GCC COUNTRIES: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 217 GCC COUNTRIES: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022-2029 (USD MILLION)
TABLE 218 GCC COUNTRIES: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022-2029 (USD MILLION)
TABLE 219 GCC COUNTRIES: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 220 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN MINIMAL RESIDUAL DISEASE TESTING MARKET
TABLE 221 MINIMAL RESIDUAL DISEASE TESTING MARKET: DEGREE OF COMPETITION
TABLE 222 MINIMAL RESIDUAL DISEASE TESTING MARKET: PRODUCT FOOTPRINT
TABLE 223 MINIMAL RESIDUAL DISEASE TESTING MARKET: TECHNOLOGY FOOTPRINT
TABLE 224 MINIMAL RESIDUAL DISEASE TESTING MARKET: APPLICATION FOOTPRINT
TABLE 225 MINIMAL RESIDUAL DISEASE TESTING MARKET: REGION FOOTPRINT
TABLE 226 MINIMAL RESIDUAL DISEASE TESTING MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 227 MINIMAL RESIDUAL DISEASE TESTING MARKET: COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS, BY PRODUCT & TECHNOLOGY
TABLE 228 MINIMAL RESIDUAL DISEASE TESTING MARKET: COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS, BY APPLICATION & END USER
TABLE 229 MINIMAL RESIDUAL DISEASE TESTING MARKET: COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS, BY REGION
TABLE 230 MINIMAL RESIDUAL DISEASE TESTING MARKET, PRODUCT LAUNCHES, JANUARY 2021-NOVEMBER 2024
TABLE 231 MINIMAL RESIDUAL DISEASE TESTING MARKET, DEALS, JANUARY 2021-NOVEMBER 2024
TABLE 232 F. HOFFMANN-LA ROCHE AG: COMPANY OVERVIEW
TABLE 233 F. HOFFMANN-LA ROCHE AG: PRODUCTS OFFERED
TABLE 234 F. HOFFMANN-LA ROCHE AG: PRODUCT LAUNCHES, JANUARY 2021-NOVEMBER 2024
TABLE 235 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY OVERVIEW
TABLE 236 LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCTS OFFERED
TABLE 237 LABORATORY CORPORATION OF AMERICA HOLDINGS: DEALS, JANUARY 2021-NOVEMBER 2024
TABLE 238 GUARDANT HEALTH, INC.: COMPANY OVERVIEW
TABLE 239 GUARDANT HEALTH, INC.: PRODUCTS OFFERED
TABLE 240 GUARDANT HEALTH, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-NOVEMBER 2024
TABLE 241 GUARDANT HEALTH, INC.: DEALS, JANUARY 2021-NOVEMBER 2024
TABLE 242 SYSMEX CORPORATION: COMPANY OVERVIEW
TABLE 243 SYSMEX CORPORATION: PRODUCTS OFFERED
TABLE 244 SYSMEX CORPORATION: PRODUCT LAUNCHES, JANUARY 2021-NOVEMBER 2024
TABLE 245 NEOGENOMICS LABORATORIES: COMPANY OVERVIEW
TABLE 246 NEOGENOMICS LABORATORIES: PRODUCTS OFFERED
TABLE 247 NEOGENOMICS LABORATORIES: DEALS, JANUARY 2021-NOVEMBER 2024
TABLE 248 MOLECULARMD (A SUBSIDIARY OF ICON PLC): COMPANY OVERVIEW
TABLE 249 MOLECULARMD (A SUBSIDIARY OF ICON PLC): PRODUCTS OFFERED
TABLE 250 ADAPTIVE BIOTECHNOLOGIES: COMPANY OVERVIEW
TABLE 251 ADAPTIVE BIOTECHNOLOGIES: PRODUCTS OFFERED
TABLE 252 ADAPTIVE BIOTECHNOLOGIES: DEALS, JANUARY 2021-NOVEMBER 2024
TABLE 253 ARCHERDX (INVITAE CORPORATION): COMPANY OVERVIEW
TABLE 254 ARCHERDX (INVITAE CORPORATION): PRODUCTS OFFERED
TABLE 255 ARCHERDX (INVITAE CORPORATION): PRODUCT LAUNCHES, JANUARY 2021-NOVEMBER 2024
TABLE 256 ARCHERDX (INVITAE CORPORATION): DEALS, JANUARY 2021-NOVEMBER 2024
TABLE 257 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
TABLE 258 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED
TABLE 259 NATERA, INC.: COMPANY OVERVIEW
TABLE 260 NATERA, INC.: PRODUCTS OFFERED
TABLE 261 OPKO HEALTH, INC.: COMPANY OVERVIEW
TABLE 262 GENETRON HEALTH: COMPANY OVERVIEW
TABLE 263 QUEST DIAGNOSTICS, INC.: COMPANY OVERVIEW
TABLE 264 ASURAGEN, INC.: COMPANY OVERVIEW
TABLE 265 INVIVOSCRIBE, INC.: COMPANY OVERVIEW
TABLE 266 ARUP LABORATORIES INC.: COMPANY OVERVIEW
TABLE 267 MISSION BIO, INC.: COMPANY OVERVIEW
TABLE 268 CERGENTIS B.V.: COMPANY OVERVIEW
List of Figures
FIGURE 1 MINIMAL RESIDUAL DISEASE TESTING MARKET SEGMENTATION & REGIONAL SCOPE
FIGURE 2 MINIMAL RESIDUAL DISEASE TESTING MARKET: RESEARCH DESIGN
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 5 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 7 MINIMAL RESIDUAL DISEASE TESTING MARKET: TOP-DOWN APPROACH
FIGURE 8 DATA TRIANGULATION METHODOLOGY
FIGURE 9 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION)
FIGURE 10 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
FIGURE 11 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
FIGURE 12 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
FIGURE 13 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY REGION, 2024 VS. 2029 (USD MILLION)
FIGURE 14 RISING INCIDENCE OF CANCER TO DRIVE MARKET GROWTH DURING FORECAST PERIOD
FIGURE 15 ASSAY KITS & REAGENTS SEGMENT TO DOMINATE MARKET IN 2029
FIGURE 16 POLYMERASE CHAIN REACTION SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 17 HEMATOLOGICAL MALIGNANCIES WILL CONTINUE TO DOMINATE MARKET IN 2029
FIGURE 18 HOSPITALS & SPECIALTY CLINICS TO BE LARGEST END USERS OF MINIMAL RESIDUAL DISEASE TESTING
FIGURE 19 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
FIGURE 20 MINIMAL RESIDUAL DISEASE TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 21 PATENT ANALYSIS FOR MINIMAL RESIDUAL DISEASE TESTING MARKET
FIGURE 22 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
FIGURE 23 MINIMAL RESIDUAL DISEASE TESTING MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 24 MINIMAL RESIDUAL DISEASE TESTING MARKET: ECOSYSTEM ANALYSIS
FIGURE 25 MINIMAL RESIDUAL DISEASE TESTING MARKET: PORTER'S FIVE FORCES ANALYSIS
FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF MRD TESTS
FIGURE 27 KEY BUYING CRITERIA FOR MINIMAL RESIDUAL DISEASE TESTING PRODUCTS
FIGURE 28 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
FIGURE 29 DEALS AND FUNDING IN MRD TESTING MARKET
FIGURE 30 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET SNAPSHOT
FIGURE 31 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET SNAPSHOT
FIGURE 32 REVENUE ANALYSIS OF KEY PLAYERS IN MINIMAL RESIDUAL DISEASE TESTING MARKET (2019-2023)
FIGURE 33 MARKET SHARE ANALYSIS OF TOP PLAYERS IN MINIMAL RESIDUAL DISEASE TESTING MARKET (2023)
FIGURE 34 MINIMAL RESIDUAL DISEASE TESTING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
FIGURE 35 MINIMAL RESIDUAL DISEASE TESTING MARKET: COMPANY FOOTPRINT
FIGURE 36 MINIMAL RESIDUAL DISEASE TESTING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
FIGURE 37 EV/EBITDA OF KEY VENDORS
FIGURE 38 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 39 BRAND COMPARISON FOR ASSAY KITS & REAGENTS
FIGURE 40 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2023)
FIGURE 41 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2023)
FIGURE 42 GUARDANT HEALTH, INC.: COMPANY SNAPSHOT (2023)
FIGURE 43 SYSMEX CORPORATION: COMPANY SNAPSHOT (2022)
FIGURE 44 MOLECULARMD (A SUBSIDIARY OF ICON PLC): COMPANY SNAPSHOT (2023)
FIGURE 45 ADAPTIVE BIOTECHNOLOGIES: COMPANY SNAPSHOT (2023)
FIGURE 46 ARCHERDX (INVITAE CORPORATION): COMPANY SNAPSHOT (2022)
FIGURE 47 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2023)
FIGURE 48 NATERA, INC.: COMPANY SNAPSHOT (2023)
